Review of pulmonary adverse effects of infliximab therapy in Crohn's disease

Expert Opin Drug Saf. 2016 Jun;15(6):769-75. doi: 10.1517/14740338.2016.1160053. Epub 2016 Mar 16.

Abstract

Introduction: Anti-inflammatory therapies are the mainstay for the treatment of inflammatory bowel disease (IBD) in children and adults, including biologics such as infliximab. While there is extensive literature on the general side effects of therapy with infliximab, the data on pulmonary adverse effects remains sparse. This article summarizes the literature related to pulmonary adverse effects of Infliximab therapy in Crohn's Disease.

Area covered: Published reports of specific pulmonary complications during ongoing therapy with infliximab in patients with IBD were included in the review. A wide variety of infectious and non-infectious complications have been reported with the use of infliximab therapy in IBD.

Expert opinion: It is important to carefully evaluate respiratory signs and symptoms in patients with IBD, especially those receiving biologic therapies. Besides infectious complications, other non-infectious pulmonary adverse effects associated with the use of infliximab should be considered in patients with IBD. Further, it is important to differentiate primary pulmonary involvement of IBD from pulmonary adverse effects of infliximab therapy. An algorithm for assessing patients with IBD presenting with pulmonary symptoms is provided as a guide for clinicians for medical decision-making.

Keywords: Adverse effects; Crohn’s Disease; Inflammatory Bowel Disease; Infliximab; Ulcerative Colitis; interstitial lung disease; tumor necrosis factor.

Publication types

  • Review

MeSH terms

  • Adult
  • Algorithms
  • Child
  • Crohn Disease / complications
  • Crohn Disease / drug therapy*
  • Gastrointestinal Agents / adverse effects
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Infliximab / adverse effects*
  • Infliximab / therapeutic use
  • Lung Diseases / chemically induced*
  • Lung Diseases / diagnosis
  • Lung Diseases / etiology

Substances

  • Gastrointestinal Agents
  • Infliximab